Abbott Laboratories — Neurology

Abbott Laboratories — Neurology

Overview

Abbott Laboratories, headquartered in Abbott Park, Illinois, is one of the world's largest healthcare companies with leading positions across medical devices, diagnostics, nutritional products, and pharmaceuticals. Within its diagnostics division, Abbott has developed a growing portfolio of neurology biomarker assays, primarily centered on the Alinity i high-throughput immunoassay platform. Abbott's neurology diagnostics strategy focuses on scalable, automated biomarker testing for Alzheimer's disease and Parkinson's disease, with particular emphasis on tau protein measurement, neurofilament light chain, and emerging α-synuclein assays. [@abbott2024]

Unlike Roche and Fujirebio, which have made neurodegeneration a primary strategic focus, Abbott's neurology franchise represents an important but not dominant part of a broader diagnostics portfolio spanning cardiovascular disease, infectious disease, oncology, and metabolic disorders. However, Abbott's vast installed base of Alinity and ARCHITECT analyzers provides significant potential for scaling neurodegeneration biomarker testing globally.

Company Background

Abbott Laboratories — Neurology

Overview

Abbott Laboratories, headquartered in Abbott Park, Illinois, is one of the world's largest healthcare companies with leading positions across medical devices, diagnostics, nutritional products, and pharmaceuticals. Within its diagnostics division, Abbott has developed a growing portfolio of neurology biomarker assays, primarily centered on the Alinity i high-throughput immunoassay platform. Abbott's neurology diagnostics strategy focuses on scalable, automated biomarker testing for Alzheimer's disease and Parkinson's disease, with particular emphasis on tau protein measurement, neurofilament light chain, and emerging α-synuclein assays. [@abbott2024]

Unlike Roche and Fujirebio, which have made neurodegeneration a primary strategic focus, Abbott's neurology franchise represents an important but not dominant part of a broader diagnostics portfolio spanning cardiovascular disease, infectious disease, oncology, and metabolic disorders. However, Abbott's vast installed base of Alinity and ARCHITECT analyzers provides significant potential for scaling neurodegeneration biomarker testing globally.

Company Background

| Attribute | Value |
|-----------|-------|
| Ticker | NYSE: ABT |
| Founded | 1888 (by Dr. Wallace Abbott) |
| Headquarters | Abbott Park, Illinois, USA |
| Diagnostics Revenue | ~$10.3 billion (2023) |
| Focus Areas | Neurology, cardiovascular, infectious disease, oncology |
| Key Platforms | Alinity i, ARCHITECT, PRISM |
| Key Assays | Tau (P-tau181, T-tau), NfL, GFAP, α-synuclein (development) |
| Website | abbott.com/diagnostics |

Alinity i Platform

Alinity i is Abbott's next-generation random-access immunoassay system, designed for high-volume clinical laboratory testing. Key features:

• Throughput: Up to 200 tests/hour
• Sample types: Serum, plasma, CSF (validated per assay)
• Modular architecture: Can be configured with clinical chemistry, hematology, and molecular diagnostics on the same platform
• Global installed base: Thousands of Alinity and ARCHITECT systems in hospitals and reference labs worldwide
• Regulatory status: FDA cleared, CE-IVD marked, PMDA approved (Japan)

Neurology Biomarker Menu

Tau Pathology:

• Alinity Tau (P-tau181) — Phosphorylated tau at threonine 181 assay. Strong performance for AD pathology detection, comparable to Elecsys and Lumipulse platforms in head-to-head validation studies. Early deployment in academic medical centers.
• Alinity Total Tau (T-tau) — General neurodegeneration marker for use within the AT(N) classification framework.

• Alinity NfL — Neurofilament light chain assay. Abbott's NfL assay has been validated for ALS, PD, and AD progression monitoring, with a broad measurement range suitable for both clinical and research applications.
• Alinity GFAP — Glial fibrillary acidic protein. Abbott GFAP demonstrates good concordance with other platforms for astrocyte reactivity measurement in AD and related disorders.

• Alinity α-Synuclein — Development-stage assay for total and oligomeric α-synuclein. Abbott is working to validate its α-synuclein assay against seed amplification methodology for PD and DLB detection. [@cullen2023]

• Alinity IL-6, TNF-α, and complement panels — Abbott has broader inflammatory biomarker menu applicable to neurodegeneration research, though these are not specifically optimized for neurological conditions.

Key Clinical Evidence

Alzheimer's Disease

Abbott tau assays have been validated in major AD research cohorts:

• BioFINDER-2 (Sweden): Abbott P-tau181 showed AUC of 0.94 for amyloid PET positivity in a cohort of 400+ subjects, with performance comparable to Quanterix Simoa and Roche Elecsys platforms. [@blennow2022]
• ADNI-3: Abbott biomarkers used for patient stratification and endpoint assessment in ongoing ADNI-3 studies.
• Katz et al. (2024): Clinical validation of Abbott Alinity P-tau181 in early AD detection showed 92% sensitivity and 85% specificity against amyloid PET across three independent cohorts. [@katz2024]
• CSF vs. plasma comparison: Abbott's assay portfolio supports both CSF and plasma biomarker testing, with plasma NfL and GFAP assays enabling less invasive testing pathways.

Parkinson's Disease

• Abbott NfL levels in PD plasma correlate with MDS-UPDRS motor scores and predict cognitive decline over 3-year follow-up in PPMI and independent cohorts.
• α-Synuclein assay development: Early studies show Abbott's assay can detect decreased total α-synuclein in CSF from PD patients vs. healthy controls, though sensitivity is lower than seed amplification assays. [@cullen2023]

Strategic Positioning

Abbott's approach to neurodegeneration diagnostics reflects its general strategy of pursuing large-scale, standardized testing markets:

• Leveraging installed base: Abbott's global Alinity/ARCHITECT installed base (15,000+ analyzers globally) offers potential for rapid deployment of neurodegeneration assays if approved for clinical use, giving Abbott advantages in reach over more specialized competitors.
• Primary care focus: Abbott is positioning its tau biomarker assays for use in primary care and general neurology settings, not just memory clinics, to enable broader screening.
• Partnership model: Abbott collaborates with pharmaceutical companies for companion diagnostic development, particularly in AD therapeutic trials.
• Integration with neuromodulation: Abbott's Infinity DBS system for PD and tremor creates a diagnostic-therapeutic loop, where biomarker testing can guide patient selection and monitoring for surgical interventions.

Comparison with Other Diagnostic Companies

| Company | Platform | Key AD Biomarker | Strength |
|---------|----------|------------------|---------|
| Abbott | Alinity i | P-tau181, NfL, GFAP | Global installed base, primary care reach |
| Roche | Elecsys | P-tau217, Aβ42, NfL | FDA breakthrough status, broad menu |
| Fujirebio | Lumipulse | P-tau217, Aβ42, P-tau181 | Japan/Europe focus, CE-marked assays |
| Quanterix | Simoa | NfL, p-tau217, GFAP | Highest sensitivity, research focus |
| Olink | Explore HT | 3,000-plex proteomics | Discovery research, biomarker panel |

Pipeline and Future Development

Abbott's neurology diagnostics pipeline includes:

• Next-generation tau assays: Improved precision P-tau181 and T-tau assays with extended dynamic range
• α-Synuclein seed amplification compatibility: Development of assays compatible with or complementary to SAA methodology
• Blood-based AD panel: Combined Aβ40/Aβ42 + P-tau181 plasma panel for primary care AD risk assessment
• TDP-43 assay: Development-stage assay for ALS and FTD
• AI-driven result interpretation: Machine learning models combining Abbott's multi-analyte panels into disease probability scores

Role in NeuroWiki Knowledge Graph

Abbott Laboratories — Neurology connects to:

• Biomarkers: [P-tau181](/biomarkers/p-tau181), [total tau](/biomarkers/tau), [NfL](/biomarkers/neurofilament-light), [GFAP](/biomarkers/gfap), [α-synuclein](/biomarkers/alpha-synuclein)
• Assay platforms: [Quanterix Simoa](/technologies/quanterix-simoa), [Meso Scale Discovery](/technologies/meso-scale-discovery), [Fujirebio Lumipulse](/companies/fujirebio-diagnostics), [Roche Elecsys](/companies/roche-diagnostics-neurology), [Olink Proteomics](/companies/olink-proteomics)
• Companies: [Abbott Laboratories](/companies/abbott-laboratories) (parent page for device/therapeutic portfolio)
• Diseases: [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [DLB](/diseases/dementia-lewy-bodies), [ALS](/diseases/amyotrophic-lateral-sclerosis)
• Research cohorts: [PPMI](/diseases/parkinsons-disease), [ADNI](/diseases/alzheimers-disease), [BioFINDER](/diseases/alzheimers-disease)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Abbott Laboratories — Neurology discovered through SciDEX knowledge graph analysis: